Graves' Disease

Graves' disease is an organ-specific autoimmune disorder caused by thyroid-stimulating antibodies (TSAb) that bind to and activate the TSH receptor on thyroid follicular cells, causing unregulated thyroid hormone production. The resulting hyperthyroidism affects virtually every organ system. Cardiovascular effects include tachycardia, atrial fibrillation, and high-output heart failure. Metabolic effects include weight loss, heat intolerance, and increased bone turnover (osteoporosis risk). Neuropsychiatric effects include anxiety, insomnia, and tremor. Graves' ophthalmopathy (thyroid eye disease) occurs in about 25-50% of patients and involves inflammation and expansion of orbital tissue, causing eye protrusion, double vision, and in severe cases, vision loss. Current treatments include antithyroid medications (methimazole, propylthiouracil), radioactive iodine therapy, and thyroidectomy. Each has significant limitations: medications have high relapse rates, while RAI and surgery result in permanent hypothyroidism. Novel approaches targeting the underlying autoimmune mechanism, including TSH receptor antibody degraders, represent a potential paradigm shift toward disease modification rather than thyroid destruction.